Role of osteoprotegerin in vascular disorders of the end-stage renal disease patients

被引：8
|
作者：
Moldovan, Diana [1 ]
Kacso, Ina Maria [1 ]
Rusu, Crina [1 ]
Potra, Alina [1 ]
Bondor, Cosmina Ioana [2 ]
Moldovan, Ioan [3 ]
Patiu, Ioan Mihai [4 ]
Vladutiu, Dan [1 ]
Caprioara, Mirela Gherman [1 ]
机构：
[1] Univ Med & Pharm Iuliu Hatieganu, Dept Nephrol, Cluj Napoca, Romania
[2] Univ Med & Pharm Iuliu Hatieganu, Dept Stat, Cluj Napoca, Romania
[3] Emergency Mil Hosp, Cluj Napoca, Romania
[4] Nefromed Dialysis Ctr, Cluj Napoca, Romania
来源：
BIOMARKERS | 2015年 / 20卷 / 02期
关键词：
Cardiovascular disease; immunotoxicity; renal disease; CHRONIC KIDNEY-DISEASE; INTIMA-MEDIA THICKNESS; SERUM OSTEOPROTEGERIN; CARDIOVASCULAR EVENTS; FETUIN-A; ELEVATED OSTEOPROTEGERIN; CALCIFICATION INHIBITORS; PLASMA OSTEOPROTEGERIN; HEMODIALYSIS; ARTERY;
D O I：
10.3109/1354750X.2014.1000376
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Aim: To assess the osteoprotegerin (OPG) relationship with cardiovascular complications in hemodialysis (HD) patients. Methods: The study included 87 HD patients. Clinical characteristics, ankle-arm index (AAI), OPG and mineral markers levels were recorded. Arterial intimal calcification (AIC) and arterial medial calcification (AMC) were registered. Results: OPG levels were increased in HD patients. Patients with AIC (p = 0.006)/ AMC (p = 0.01) had higher OPG levels. OPG did not have any relation with cardiovascular diseases. OPG correlated positively with age, increased HD vintage and inversely with albumin and AAI. OPG has not been a risk factor for VC or cardiovascular disease. Conclusion: OPG rising could be a reaction in defense to vascular aggression, because OPG was associated with VC, but not with vascular disease.
引用
收藏
页码：116 / 122
页数：7
相关论文
共 50 条
  • [21] Role of homocysteine in end-stage renal disease
    Wu, Chia-Chao
    Zheng, Cai-Mei
    Lin, Yuh-Feng
    Lo, Lan
    Liao, Min-Tser
    Lu, Kuo-Cheng
    CLINICAL BIOCHEMISTRY, 2012, 45 (16-17) : 1286 - 1294
  • [22] The role of homocysteine in end-stage renal disease
    Yeun, JY
    SEMINARS IN DIALYSIS, 1998, 11 (02) : 95 - 101
  • [23] Vascular and cardiac infections in end-stage renal disease
    Manian, FA
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2003, 325 (04): : 243 - 250
  • [24] Hyperphosphatemia calcification in and vascular end-stage renal disease
    Nishizawa, Y
    Jono, S
    Ishimura, E
    Shioi, A
    JOURNAL OF RENAL NUTRITION, 2005, 15 (01) : 178 - 182
  • [25] Vascular and cardiac remodeling in end-stage renal disease
    London, GM
    Marchais, SJ
    Guerin, AP
    Metivier, F
    Pannier, B
    NEFROLOGIA, 1997, 17 : 17 - 22
  • [26] HYPERTENSIVE END-STAGE RENAL-DISEASE IN BLACKS - THE ROLE OF END-STAGE RENAL-DISEASE SURVEILLANCE
    MCCLELLAN, W
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 21 (04) : 25 - 30
  • [27] Renal ablation in patients with end-stage renal disease
    Hansch, A.
    Pfeil, A.
    Neumann, R.
    Neumann, S.
    Mayer, T. E.
    Wolf, G.
    VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, 2011, 40 (04) : 308 - 314
  • [28] ACUTE VASCULAR INTESTINAL DISEASE IN PATIENTS WITH END-STAGE RENAL DISEASE: A NATIONAL ANALYSIS
    Rizwan, Rabia
    Chaar, Abdelkader
    Sehgal, Kanika
    Richter, Tyler
    Nawaz, Ahmad
    Patel, Shanti
    Feuerstadt, Paul
    GASTROENTEROLOGY, 2024, 166 (05) : S1033 - S1033
  • [29] The role of interventional radiology in management of patients with end-stage renal disease
    Surlan, M
    Popovic, P
    EUROPEAN JOURNAL OF RADIOLOGY, 2003, 46 (02) : 96 - 114
  • [30] Impact of vascular access on myocardial function in patients with end-stage renal disease
    Mendes, L.
    Natario, A.
    Santos, J. F.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S193 - S193
12345